Abstract:Background: During the last decades significant progress has been made in the management of patients with pancreatic neuroendocrine tumors.It is unclear how the type of the health care facility at which treatment occurs may patients outcomes.Methods: Data from pancreatic neuroendocrine tumors (pNETs) reported to the National Cancer Data Base (NCDB) between 2004-2016 were examined.Type of institutions were: Academic/Research Cancer Program (ARP), Comprehensive Community Cancer Program (CCCP); Integrated Network Cancer Program(INCP) and Community Cancer Program (CCP).Multivariate Cox proportional hazard models were used to evaluate the effect of cofactors including institution type on overall survival.Results: A total of 17,887 patients with pNETs were analyzed.The majority of patients were treated at an Academic/Research Program (ARP) (n = 10013, 56%).Patients treated at ARP were younger (ARP = 61.7yrsvs CCCP = 64.6yrs,CCP = 65.4yrs,INCP = 63yrs; p<0.001) and a higher percentage had a Charlson/ Deyo score of 0 (ARP = 72.6%,CCCP = 67.7%,CCP = 69.4%,INCP = 67.9%;p<0.001).Treatment at ARPs was significantly associated with receipt of surgery (ARP = 59.7% vs CCCP = 39.4% vs CCP = 22% vs INCP = 51.6%;p<0.001), trend that persisted both for very early tumors 2 cm (ARP = 74.7%vs CCCP = 66.5% vs CCP: 52.4% vs INCP:71.6%;p<0.001) as well as for patients with liver metastases (ARP: 21.3% vs CCCP: 10.6% vs CCP: 5% vs INCP: 16.8%; p<0.001) .Treatment at ARPs was associated with improved survival (median OS: ARPs:91mo, CCCP:47mo, CCP:24.5, INCP:72mo; p<0.001) and this difference persistent for stages 1, 2 and 4.After adjusting for age, gender, race, education, insurance status, income, CDC, stage and surgery status treatment at ARPs was associated with decreased mortality (HR(95%CI): ARP:ref, CCCP:1.19(1.12-1.26);p<0.0001,CCP:1.24(1.11-1.39);p<0.0001,INCP:1.14(1.05-1.24);p<0.001).Conclusion: Treatment at academic/research programs is associated with more frequent resections both for early as well as metastatic pNETs and best survival outcomes.This effect in overall survival appears to exist for early and late stages and after adjusting for known cofactors.Figure .Overall Survival (OS) of 15362 patients with pancreatic neuroendocrine tumors (stages 1-4) stratified according to institution type.Median OS was greater for ARP (91mo, n = 8619) followed by INCP (72mo, n = 1846), CCCP (47mo, n = 4253) and CCP (24.5mo, n = 644) (p<0.001)(NCDB 2004(NCDB -2016) )

Survival benefit of local consolidative therapy for patients with single-organ metastatic pancreatic cancer: a propensity score-matched cross-sectional study based on 17 registries

Laparoscopic versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a single-center propensity score matching study

Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study

Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis

Total Laparoscopic Versus Open Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Propensity Score Matching Analysis with Meta-Analysis

Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases.

Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer with Lung Metastasis: Results from a Large Retrospective Study

Combined Ablation-Chemotherapy Versus Chemotherapy Alone for Pancreatic Cancer with Liver Metastasis: a Propensity Score Matching Study

Does Surgical Resection Significantly Prolong the Long-Term Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma? A Cross-Sectional Study Based on 18 Registries

Whether Early Stage Pancreatic Ductal Adenocarcinoma Patients Could Benefit from the Post-Operation Chemotherapy Regimens: a SEER-based Propensity Score Matching Study.

Surgery and Combined Transplant with Chemotherapy Improve Survival for Patients with Liver Limited and Locally Advanced Intrahepatic Cholangiocarcinoma: a Seer Database Analysis

Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma

Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy

Locally advanced pancreatic cancer: Is surgical palliation associated with improved clinical outcome relative to medical palliation?

Long-term Outcomes of Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Chinese Multi-Center Prospective Randomized Controlled Trial.

Survival Benefit and Impact of Adjuvant Chemotherapy Following Systemic Neoadjuvant Chemotherapy in Patients with Resected Pancreas Ductal Adenocarcinoma: a Retrospective Cohort Study.

The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer

A Multicenter Retrospective Study with Propensity Score Matching

Clinical outcome comparison of laparoscopic radical antegrade modular pancreatosplenectomy vs. laparoscopic distal pancreatosplenectomy for left-sided pancreatic ductal adenocarcinoma surgical resection

The survival impact of palliative radiotherapy on synchronous metastatic pancreatic ductal adenocarcinoma: metastatic site can serve for radiotherapy-decision

Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy